Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.

T M Mulders1, P F Bruning, J M Bonfrer

  • 1Department of Clinical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoekhuis, Amsterdam.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
|February 1, 1990
PubMed
Summary

Prostate-specific antigen (PSA) shows promise for monitoring prostate cancer recurrence and response to treatment. However, serum PSA assays lack sufficient sensitivity and specificity for initial diagnosis and staging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The onset of puberty and the availability of sex steroids in female gymnasts.

American journal of human biology : the official journal of the Human Biology Council·2017
Same author

S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·2007
Same author

Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions.

The British journal of ophthalmology·2006
Same author

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005
Same author

Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.

Melanoma research·2003
Same author

Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay.

Clinical chemistry·2001

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • Noninvasive methods for prostate cancer diagnosis, staging, and therapy response evaluation often lack sufficient sensitivity or specificity.
  • Prostate-specific antigen (PSA), identified in 1979, is an organ-specific glycoprotein found in most prostatic carcinomas, normal prostatic tissue, and benign prostatic hypertrophy (BPH).

Purpose of the Study:

  • To review the utility of prostate-specific antigen (PSA) as a biomarker in prostate cancer.
  • To evaluate PSA's role at both serum and tissue levels for diagnosis, staging, and treatment monitoring.

Main Methods:

  • Review of existing literature on prostate-specific antigen (PSA) in prostate cancer.
  • Analysis of PSA's performance in serum assays and tissue-level immunohistochemistry.

Related Experiment Videos

Main Results:

  • Serial monitoring of serum PSA concentrations aids in detecting residual/recurrent tumors and evaluating response to systemic treatment in advanced disease.
  • Immunohistochemical detection of PSA can assist in identifying metastatic tumors of unknown origin.
  • PSA serum assays are not sufficiently sensitive or specific for primary tumor staging or screening.

Conclusions:

  • Prostate-specific antigen (PSA) is a valuable marker for monitoring prostate cancer treatment response and recurrence.
  • PSA is a more sensitive marker for prostate carcinoma than prostatic acid phosphatase.
  • Current PSA serum assays are inadequate for definitive diagnosis, staging, or screening of prostate cancer.